Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

NCT01405391 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

NCT04272034 ·Status: TERMINATED ·Phase: PHASE1

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

NCT04397276 ·Status: COMPLETED ·Phase: PHASE1

Evaluate Eribulin ORA in Subjects With Solid Tumors

NCT04013217 ·Status: TERMINATED ·Phase: PHASE1

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

NCT04336241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

NCT05841563 ·Status: RECRUITING ·Phase: PHASE1

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors

NCT05940571 ·Status: COMPLETED ·Phase: PHASE1

PM534 Administered Intravenously to Patients With Advanced Solid Tumors

NCT05835609 ·Status: RECRUITING ·Phase: PHASE1

A Study of YL242 in Subjects With Advanced Solid Tumors

NCT07197827 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

NCT00820560 ·Status: COMPLETED ·Phase: PHASE1

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors

NCT00404521 ·Status: TERMINATED ·Phase: PHASE1

Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor

NCT05146440 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

NCT05126433 ·Status: TERMINATED ·Phase: PHASE2

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

NCT03833427 ·Status: TERMINATED ·Phase: PHASE1

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

NCT02030067 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of AS1411 in Advanced Solid Tumours

NCT00881244 ·Status: COMPLETED ·Phase: PHASE1

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors

NCT06771921 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

NCT02189174 ·Status: TERMINATED ·Phase: PHASE1

Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

NCT04053673 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

NCT06873789 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

NCT01830231 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

NCT06859762 ·Status: RECRUITING ·Phase: PHASE1

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

NCT02711345 ·Status: TERMINATED ·Phase: PHASE1

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

NCT00954512 ·Status: TERMINATED ·Phase: PHASE1/PHASE2